TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06265272

Intervention type: DRUG
Intervention: Injection of a gadolinium contrast agen
Description: All patients will be requested to have an injection of a gadolinium contrast agent, which may be either Gadavist (Bayer, Whippany, NJ, USA), Eovist (Bayer, Whippany, NJ, USA), or Dotarem (Guerbet, Princeton, NJ, USA) (ancillary drugs).~* About halfway through the examination, the same intravenous catheter used to inject the radiotracer will be used to inject the MRI contrast agent;~* After being positioned on the PET/MRI table, the nuclear medicine technicians will connect the patient to the MRI-safe power-injector; - The catheter will be flushed before and after injection with 0.9% saline solution;

Intervention type: DRUG
Intervention: Radiotracer Injection
Description: All patients will be requested to have a radiotracer injection of Ga-PSMA (Illucix, Telix Pharmaceuticals). An intravenous catheter will be placed in an arm or hand vein for injection of the Ga-PSMA;~* The catheter will be flushed post-injection with 0.9% saline solution~* The injected dose and the time of injection will be recorded.~* The subjects will be positioned on the scanner table; support devices under the back and/or legs will be used to enable the patient to comfortably maintain his/her position throughout the scan

Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging
Description: PET, MRI and fused PET/MRI images will be qualitatively assessed in comparison to standard of reference data. For PET, standard of reference will be PET images as obtained by standard PET acquisition mode. Attenuation correction of the PET images will be performed using a 2-point Dixon MRI sequence and a vendor-specific atlas-based attenuation map. 3D scatter correction by single scatter simulation is also performed using the MRI-derived attenuation data. MRI images will be compared to dedicated 3 Tesla MR upper abdominal protocol images acquired at the MGH in patients with liver cirrhosis, including those undergoing imaging follow-up after systemic or local regional therapies. For PET/MRI fused images, the standard of reference will be co-registered and fused PET/MRI images as obtained by standard MRI sequences/reconstructions.
Study: NCT05793801

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dressing change
Description: The patient circuit corresponds to that of usual care.~Not part of usual patient management:~* The rhythm of PICCline dressing changes, which differed between the two groups.~* The collection of pain on a visual analog scale at each dressing change.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dressing change
Description: The patient circuit corresponds to that of usual care.~Not part of usual patient management:~* The rhythm of PICCline dressing changes, which differed between the two groups.~* The collection of pain on a visual analog scale at each dressing change.
Study: NCT05284448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentoxifylline (Trental SR®)
Description: 400 mg three times daily
Study: NCT04323488

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lindamood-Bell Seeing Stars
Description: Seeing Stars in a curriculum developed by Lindamood-Bell. It is published and openly available. It involves systematic training in the building blocks of skilled reading.
Study: NCT05349981

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phonak Lyric self-replacement procedure
Description: The self-replacement procedure is an experimental procedure in which the Lyric user replaces the Lyric devices independently at every other device replacement, using dedicated candidacy, training, and management procedures, conducted by and at the discretion of his/her hearing care provider (HCP).
Study: NCT05154123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: AT-527 + rosuvastatin
Description: * Day 1: A single dose of rosuvastatin will be administered.~* Day 8: A single dose of AT-527 and rosuvastatin will be co-administered.
Study: NCT05143229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: PI3K inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: PI3K inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: PI3K inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Description: Trop-2-directed antibody and topoisomerase inhibitor drug conjugate
Study: NCT05154123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527 + rosuvastatin
Description: * Day 1: A single dose of rosuvastatin will be administered.~* Day 8: A single staggered dose of AT-527 and rosuvastatin will be administered (2 hours later)
Study: NCT05306093

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutraceutical
Description: Food supplements are consumed during 8 weeks by healthy volunteers

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Food supplements are consumed during 8 weeks by healthy volunteers
Study: NCT05143229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Description: Trop-2-directed antibody and topoisomerase inhibitor drug conjugate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Description: Trop-2-directed antibody and topoisomerase inhibitor drug conjugate
Study: NCT05256459

Intervention type: OTHER
Intervention: Long term follow-up
Description: No extra intervention.
Study: NCT06077773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral EP262
Description: Once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral EP262
Description: Once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral EP262
Description: Once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily
Study: NCT04847284

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy
Description: Intraoperative radiotherapy application immediately following resection of brain metastases.
Study: NCT06057662

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: personalized comprehensive diabetes support
Description: personalized comprehensive diabetes support
Study: NCT05208528

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ES1 group
Description: Participants will intake 2 capsules of 300 mg/capsule with 50 mg of Bifidobacterium longum ES1 (1E09 CFU of probiotic/day, by taking 2 capsules) and 250 mg of maltodextrin.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HT-ES1 group
Description: Participants will intake 2 capsules of 300 mg/capsule with 50 mg of HT-ES1 (1E09 CFU of probiotic/day, by taking 2 capsules) and 250 mg of maltodextrin.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Participants will intake 2 capsules of 300 mg/capsule with 300 mg of maltodextrin.
Study: NCT05054413

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT05231746

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hSTC810
Description: hSTC810 will be administered as an intravenous infusion (IV)
Study: NCT05674630

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magic Touch drug eluting balloon based strategy
Description: Adult patients with chronic coronary syndrome deemed suitable for percutaneous intervention and significant long de-novo coronary lesion randomized in the experimental arm will receive treatment with drug eluting balloon (Magic Touch®) followed by invasive follow up (FFR and IVUS) at 6 ot 12 months in a randomized fashion.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug-eluting stent-based strategy
Description: Adult patients with chronic coronary syndrome deemed suitable for percutaneous intervention and significant long de-novo coronary lesion randomized in the control arm will receive treatment with drug-eluting stent followed by invasive follow up (FFR and IVUS) at 6 ot 12 months in a randomized fashion.
Study: NCT04953364

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART
Description: SMART includes mental and physical wellness, residual/prosthetic limb managements, use of a prosthesis and weekly peer-support calls or video call over Zoom, hosted by University of British Columbia, depends on participant's preference, promoting motivation and establishing goal setting and action planning. The tablet will also allow asynchronous contact with trainers through a secure website.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control group will receive a care booklet and weekly contacts for 6 weeks.
Study: NCT05823246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLF31907
Description: Intravenous infusion once every two weeks. The dose administered in part 2 will depend on the outcome of part 1.
Study: NCT05616741

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerebri biofeedback
Description: Daily use of a mobile application connected with two wireless sensors for measurement of muscle tension, heart rate variability, and peripheral finger temperature, to be used for home-based biofeedback treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cerebri headache diary
Description: Daily registration of headache and medication with the Cerebri mobile application. This intervention is identical for both study arms.

Intervention type: OTHER
Group type: OTHER
Intervention: Cerebri headache diary
Description: Daily registration of headache and medication with the Cerebri mobile application. This intervention is identical for both study arms.
Study: NCT05583552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imetelstat sodium
Description: Intravenous injection
Study: NCT04710732

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Enoxaparin 40 mg once-daily before randomization
Description: Once-daily subcutaneous injection of a standard prophylactic dose of Enoxaparin 40 mg according to the set schedule:~* 12 hours before the surgery (if applicable) on a postoperative day -1 (POD -1)~* 6-12 hours after the surgery (key injection 1) on the surgery day (POD 0)~* 12 hours after the previous key injection 1 (key injection 2) on the POD 1~* 24 hours after the previous key injection 2 on the POD 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Enoxaparin 40 mg once-daily before randomization
Description: Once-daily subcutaneous injection of a standard prophylactic dose of Enoxaparin 40 mg according to the set schedule:~* 12 hours before the surgery (if applicable) on a postoperative day -1 (POD -1)~* 6-12 hours after the surgery (key injection 1) on the surgery day (POD 0)~* 12 hours after the previous key injection 1 (key injection 2) on the POD 1~* 24 hours after the previous key injection 2 on the POD 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Enoxaparin 40 mg once-daily after randomization
Description: Once-daily subcutaneous injection (every 24 hours) of a standard prophylactic dose of Enoxaparin 40 mg since POD 3 and until discharge

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escalated Enoxaparin 30 mg twice-daily after randomization
Description: Twice-daily subcutaneous injection (every 12 hours) of an escalated prophylactic dose of Enoxaparin 30 mg since POD 3 and until discharge

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anti-embolic elastic compression stockings
Description: Applied before or just after the surgery and used around the clock until discharge

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anti-embolic elastic compression stockings
Description: Applied before or just after the surgery and used around the clock until discharge

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Thrombodynamic test (TD)
Description: Blood sampling for TD:~* 12 hours after key injection 1 (TD-12) on the POD 1~* 24 hours after key injection 2 (TD-24) on the POD 2~* 24 hours after each daily injection on the POD 4 (TD-4) and POD 5 (TD-5)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Thrombodynamic test (TD)
Description: Blood sampling for TD:~* 12 hours after key injection 1 (TD-12) on the POD 1~* 24 hours after key injection 2 (TD-24) on the POD 2~* 24 hours after each daily injection on the POD 4 (TD-4) and POD 5 (TD-5)
Study: NCT06479096

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brush / Espresso Mild Prototype
Description: Subjects will brush and rinse with their assigned mouthwash twice daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brush / Espresso Intense Prototype
Description: Subjects will brush and rinse with their assigned mouthwash twice daily.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brush / Fresh Breath Oral Rinse
Description: Subjects will brush and rinse with their assigned mouthwash twice daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Brush / Hydroalcohol
Description: Subjects will brush and rinse with their assigned mouthwash twice daily.
Study: NCT05109117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAP Unscented
Description: Sunscreen lip balm.
Study: NCT05035368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ladarixin
Description: Ladarixin will be administered orally at the dose of 400 mg twice a day at about 12-hour interval (morning and evening).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ladarixin
Description: Ladarixin will be administered orally at the dose of 400 mg twice a day at about 12-hour interval (morning and evening).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is administered with the same schedule of Ladarixin.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is administered with the same schedule of Ladarixin.
Study: NCT05962983

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Small Steps for Big Changes Program
Description: Participants will be asked to attend six one on one sessions providing diet and exercise counselling each lasting 20-30 minutes over the course of six weeks. The nutrition counselling will introduce participants to a healthy dietary changes for reducing added sugar intake and refined/processed carbohydrate intake as well as increasing vegetable consumption. After counselling sessions, participants will complete their chosen form of aerobic exercise: 1) traditional continuous exercise that involves exercising at a constant pace for 20-30 minutes (moderate-intensity continuous training, MICT); or 2) interval exercise that involves alternating between 30 seconds and 1-minute of brisk exercise and 1-minute of easy exercise for \~15 min (high-intensity interval training, HIIT). Both exercise forms could be completed on treadmill, elliptical or stationary bike. In total, each session will last approximately one hour.
Study: NCT05333029

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic mesenchymal stromal cells (MSCs)
Description: Treatment dose 2 x10\^6 cells/kg (+/- 20%)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Extracorporeal photopheresis (ECP)
Description: Blood is collected through an intravenous (IV) line which is connected to an apheresis machine.The machine adds a chemical that makes the white blood cells sensitive to light. Then the machine shines a light on the cells and then returns the blood to the participant
Study: NCT06288659

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraventricular intracranial pressure monitoring
Description: The postoperative management of ICP is guided by quantifiable Intraventricular ICP parameters. The remaining treatments are consistent with those in the control group.
Study: NCT05147792

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLAAS
Description: CLAAS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WATCHMAN left atrial appendage closure device / Amulet left atrial appendage occluder
Description: WATCHMAN left atrial appendage closure device / Amulet left atrial appendage occluder
Study: NCT05775510

Intervention type: DEVICE
Intervention: Commercially available neurostimulation systems
Description: Spinal cord stimulation therapy delivered during trialing and following implant of commercially available neurostimulation systems

Intervention type: DEVICE
Intervention: Commercially available neurostimulation systems
Description: Spinal cord stimulation therapy delivered during trialing and following implant of commercially available neurostimulation systems
Study: NCT06602479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0618
Description: MEDI0618 per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0618
Description: MEDI0618 per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0618
Description: MEDI0618 per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0618
Description: MEDI0618 per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0618
Description: MEDI0618 per protocol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Volume-matched placebo for all arms

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Volume-matched placebo for all arms
Study: NCT04196218

Intervention type: OTHER
Group type: OTHER
Intervention: Driving simulator
Description: Computer simulated driving assessment
Study: NCT06299683

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial Treatment
Description: The psychosocial self-management intervention consists of 8 weekly 50-minute individual visits with an assigned trained therapist. Sessions follow a structured protocol that has been developed with the patient population and tested in a prior study. Treatment modules are individualized and include topics such as pain coping strategies, relaxation training, education on IC/BPS, and communication strategies.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Floor Physical Therapy
Description: The pelvic floor physical therapy condition consists of 10 weekly 45-minute individual visits with an assigned trained physical therapist. In IC/BPS, pelvic floor physical therapy (PT) uses manual manipulation to release localized muscle tension, trigger points, and correct other scars and restrictions to reduce pain and urgency symptoms. Specific techniques will include external connective tissue manipulation to the abdominal wall, back, buttocks and thighs, myofascial trigger point release, and internal transvaginal/transrectal treatment of the soft tissues of the pelvic floor with connective tissue and myofascial manipulation to pelvic floor musculature
Study: NCT06605534

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LungTalk
Description: Tailored lung screening intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-tailored lung screening
Description: Non-tailored lung screening. It involves the addition of education to Social Determinants of Health (SDOH) screening and referral with patient navigation. Patients will be identified, and screened for SDOH needs using the UniteUs SDOH screener that is embedded in the Electronic Health Record (EHR), and connected to geographically-tailored resources (as described above under Arm 1). Participants will then be sent a non-tailored lung screening educational brochure via email to review that details lung cancer risk, lung screening facts, benefits, and potential harms. Within 48 hours, the Community Outreach and Engagement (COE) Patient Navigator will contact the patient to answer questions and provide navigation services as described above in Arm 1.
Study: NCT06606327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazoxide, 3 mg/kg per dose
Description: Insulin anti-secretagogue taken for 8 doses over 4 days
Study: NCT06589791

Intervention type: OTHER
Intervention: No treatment given
Description: Online self-completion survey
Study: NCT06587035

Intervention type: DRUG
Intervention: Somatrogon
Description: Long-acting growth hormone for pediatric growth hormone deficiency.
Study: NCT06587932

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: brain gym exercises
Description: It is comprised very easy body movements which have been designed to coax the two hemispheres of the brain.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional treatments
Description: traditional treatment in form of balance training included standing on one leg, standing in tandem mode, walking in a tandem mode (one foot in front of the other), walking on toes and heels, side walk, standing while one upper extremity and the opposite lower extremity were up, rotating the head from side to side, walking backwards for four steps, and shifting weight from one foot to the other
Study: NCT06503510

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Histamine
Description: A small drop of histamine dihydrochloride (1%, in saline) will be applied to a previously determined area on the volar forearm followed by a prick through the drop.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cowhage
Description: Approximately 30-35 cowhage spicules will be manually inserted into the subject's skin.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bovine adrenal medulla (BAM8-22)
Description: A small drop of BAM8-22 solution will be applied to a previously determined area on the volar forearm followed by a prick through the drop.
Study: NCT05909904

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tislelizumab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-A425
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-A425
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBL-007
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBL-007
Description: Administered intravenously
Study: NCT06590467

Intervention type: DEVICE
Intervention: Amplatzer™ Occlusion Devices
Description: The Amplatzer™ Occluders are devices intended for the occlusion of multiple septal heart defects.

Intervention type: DEVICE
Intervention: Epic™ Surgical Tissue Heart Valve devices
Description: The Epic™ valves are indicated for patients requiring replacement of a diseased, damaged, or malfunctioning native aortic/mitral heart valve. It may also be used as a replacement for a previously implanted aortic/mitral prosthetic heart valve.
Study: NCT06215586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tovinontrine (CRD-750
Description: Tablets administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets administered orally